Portola Pharmaceuticals Inc Revenue Growth Rates (PTLA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Portola Pharmaceuticals inc   (NASDAQ: PTLA)
 

PTLA's Revenue Growth by Quarter and Year

Portola Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PTLA Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 26.39
FY 26.39

PTLAs Annual Revenue
Portola Pharmaceuticals Inc 's Revenue in the fiscal year 2019 $ 116.64 millions
Portola Pharmaceuticals Inc 's Revenue in the fiscal year 2018 $ 40.13 millions
Portola Pharmaceuticals Inc 's Revenue in the fiscal year 2017 $ 22.55 millions
Portola Pharmaceuticals Inc 's Revenue in the fiscal year 2016 $ 35.50 millions
Portola Pharmaceuticals Inc 's Revenue in the fiscal year 2015 $ 12.07 millions




PTLA Revenue first quarter 2020 Y/Y Growth Comment
Portola Pharmaceuticals inc reported Revenue increase of 19.03% year on year in the first quarter 2020, to $ 26.39 millions, this is lower than Portola Pharmaceuticals Inc 's recent average Revenue surge of 111.64%.

Looking into first quarter 2020 results within Major Pharmaceutical Preparations industry 92 other companies have achieved higher Revenue growth. While Portola Pharmaceuticals Inc ' s Revenue growth of 19.03% ranks overall at the positon no. 780 in the first quarter 2020.


PTLA Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 91.18 % 56.12 % -28.41 %
3rd Quarter September - 159.52 % 270.23 % -58.91 %
2nd Quarter June - 608.73 % 5.8 % -10.4 %
1st Quarter March 19.03 % 233.89 % 29.43 % -37.89 %
FY   - 190.66 % 77.96 % -

Financial Statements
Portola Pharmaceuticals Inc 's first quarter 2020 Revenue $ 26.39 millions PTLA's Income Statement
Portola Pharmaceuticals Inc 's first quarter 2019 Revenue $ 22.17 millions Quarterly PTLA's Income Statement


PTLA Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - -20.52 % 7.9 % 155.87 %
3rd Quarter September - 29.49 % 253.62 % 1.06 %
2nd Quarter June - 28.19 % -39.61 % -26.12 %
1st Quarter March -9.78 % 44.9 % -32.24 % -62.53 %
FY (Year on Year)   - 190.66 % 77.96 % -


Back to PTLA Growth rate Comparisons >> Back to PTLA Growth rate Comparisons >>


Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #93
Healthcare Sector #196
Overall #780

Revenue Y/Y Growth Statistics
High Average Low
608.65 % 111.64 % -68.83 %
(Jun 30 2019)   (Dec 31 2017)
Revenue first quarter 2020 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #93
Healthcare Sector #196
Overall #780
Revenue Y/Y Growth Statistics
High Average Low
608.65 % 111.64 % -68.83 %
(Jun 30 2019)   (Dec 31 2017)

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Portola Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
253.45 % 25.43 % -62.55 %
(Sep 30 2018)  


PTLA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Portola Pharmaceuticals Inc disclosed drop in Revenue from the fourth quarter by -9.78% to $ 26.39 millions, from $ 29.25 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2020 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 142 other companies have achieved higher Revenue quarter on quarter growth. While Portola Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2317.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #143
Healthcare Sector #326
Overall #2317
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #143
Healthcare Sector #326
Overall #2317
Revenue Q/Q Growth Statistics
High Average Low
253.45 % 25.43 % -62.55 %
(Sep 30 2018)  


PTLA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2020 Portola Pharmaceuticals Inc disclosed drop in Revenue from the fourth quarter by -9.78% to $ 26.39 millions, from $ 29.25 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2020 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 142 other companies have achieved higher Revenue quarter on quarter growth. While Portola Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 2317.


Portola Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)
Cumulative Revenue 12 Months Ending $ 120.86 $ 116.64 $ 102.69 $ 80.07 $ 55.66
Y / Y Revenue Growth (TTM) 117.16 % 190.66 % 196.49 % 229.69 % 131.3 %
Year on Year Revenue Growth Overall Ranking # 173 # 59 # 23 # 31 # 111
Seqeuential Revenue Change (TTM) 3.62 % 13.58 % 28.25 % 43.86 % 38.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 429 # 250 # 44 # 95 # 42


Cumulative Revenue growth Comment
Assuming the Portola Pharmaceuticals Inc 's fiscal year would have ended in Mar 31 2020, Portola Pharmaceuticals Inc would have reprted above average annual Revenue surge of 117.16% year on year, of $ 121 millions.
This marks a slow-down of the companys growth trends and from the 190.66% surge in Dec 31 2019.

In the Healthcare sector 51 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 59 to 173.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 55
Healthcare Sector # 52
Overall # 173

Revenue TTM Y/Y Growth Statistics
High Average Low
327.01 %
 109.67 %
-57.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 112
S&P 500 # 429
Cumulative Revenue growth Comment
Assuming the Portola Pharmaceuticals Inc 's fiscal year would have ended in Mar 31 2020, Portola Pharmaceuticals Inc would have reprted above average annual Revenue surge of 117.16% year on year, of $ 121 millions.
This marks a slow-down of the companys growth trends and from the 190.66% surge in Dec 31 2019.

In the Healthcare sector 51 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 59 to 173.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 55
Healthcare Sector # 52
Overall # 173

Revenue TTM Y/Y Growth Statistics
High Average Low
327.01 %
109.67 %
-57.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 112
S&P 500 # 429




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PTLA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Mar 31 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2020
Serina Therapeutics Inc 32.73%$ 32.732 millions
Viemed Healthcare Inc 31.42%$ 31.416 millions
Inspire Medical Systems inc 31.37%$ 31.366 millions
Novaccess Global Inc31.30%$ 31.300 millions
Sarepta Therapeutics Inc 30.64%$ 30.643 millions
Scorpius Holdings inc 28.64%$ 28.645 millions
Clovis Oncology inc 28.52%$ 28.522 millions
Precision Biosciences Inc28.12%$ 28.122 millions
Alector Inc 27.94%$ 27.939 millions
Quanterix Corporation27.48%$ 27.478 millions
Ptc Therapeutics inc 27.39%$ 27.389 millions
Koru Medical Systems Inc 27.25%$ 27.255 millions
Horizon Therapeutics Public Limited Company26.94%$ 26.942 millions
Stablecoin Development Corporation26.89%$ 26.895 millions
Alexion Pharmaceuticals Inc 26.69%$ 26.692 millions
Amneal Pharmaceuticals Inc 26.54%$ 26.540 millions
Schrodinger Inc 26.19%$ 26.194 millions
Clearpoint Neuro Inc 26.01%$ 26.009 millions
Sorrento Therapeutics Inc 25.69%$ 25.688 millions
Repligen Corp25.49%$ 25.491 millions
Biomarin Pharmaceutical Inc25.28%$ 25.284 millions
1life Healthcare Inc 24.99%$ 24.990 millions
Adamas Pharmaceuticals Inc24.14%$ 24.141 millions
Pro dex Inc 24.13%$ 24.132 millions
Insulet Corporation24.10%$ 24.095 millions
Intellia Therapeutics Inc 23.80%$ 23.799 millions
Akorn Inc23.40%$ 23.405 millions
Catalent Inc 23.17%$ 23.174 millions
Oncternal Therapeutics Inc 22.98%$ 22.979 millions
Avinger Inc 22.88%$ 22.880 millions


About Portola Pharmaceuticals Inc Revenue Growth Rates (PTLA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.